Organon (OGN) Acquires Forendo Pharma from Karolinska Development for Up to $945M
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- S&P 500, Dow set for higher open with focus on Mideast developments
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Don’t expect a grand bargain from the Trump-Xi summit: Yardeni
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Organon (OGN) Tops Q3 EPS by 23c
November 11, 2021 6:34 AM ESTOrganon (NYSE: OGN) reported Q3 EPS of $1.67, $0.23 better than the analyst estimate of $1.44. Revenue for the quarter came in at $1.6 billion versus the consensus estimate of $1.58 billion.
GUIDANCE:
Organon sees FY2021 revenue of $6.2-6.3 billion, versus the consensus of $6.28... More
